Cost-effectiveness of norovirus vaccination in children in Peru

Andrew J. Mirelman, Sarah Blythe Ballard, Mayuko Saito, Margaret Kosek, Robert H Gilman

Research output: Contribution to journalArticle

Abstract

Background: With candidate norovirus (NV) vaccines in a rapid phase of development, assessment of the potential economic value of vaccine implementation will be necessary to aid health officials in vaccine implementation decisions. To date, no evaluations have been performed to evaluate the benefit of adopting NV vaccines for use in the childhood immunization programs of low- and middle-income countries. Methods: We used a Markov decision model to evaluate the cost-effectiveness of adding a two-dose NV vaccine to Peru's routine childhood immunization schedule using two recent estimates of NV incidence, one for a peri-urban region and one for a jungle region of the country. Results: Using the peri-urban NV incidence estimate, the annual cost of vaccination would be $13.0 million, offset by $2.6 million in treatment savings. Overall, this would result in 473 total DALYs averted; 526,245 diarrhea cases averted;153,735 outpatient visits averted; and 414 hospitalizations averted between birth and the fifth year of life. The incremental cost-effectiveness ratio would be $21,415 per DALY averted; $19.86 per diarrhea case; $68.23 per outpatient visit; and $26,298 per hospitalization. Using the higher jungle NV incidence rates provided a lower cost per DALY of $10,135. The incremental cost per DALY with per-urban NV incidence is greater than three times the 2012 GDP per capita of Peru but the estimate drops below this threshold using the incidence from the jungle setting. In addition to the impact of incidence, sensitivity analysis showed that vaccine price and efficacy play a strong role in determining the level of cost-effectiveness. Conclusions: The introduction of a NV vaccine would prevent many healthcare outcomes in the Peru and potentially be cost-effective in scenarios with high NV incidence. The vaccine cost-effectiveness model could also be applied to the evaluation of NV vaccine cost-effectiveness in other countries. In resource-poor settings, where NV incidence rates are expected to be higher.

Original languageEnglish (US)
Pages (from-to)3084-3091
Number of pages8
JournalVaccine
Volume33
Issue number27
DOIs
StatePublished - Jun 17 2015

Fingerprint

Norovirus
Peru
cost effectiveness
Cost-Benefit Analysis
Vaccination
vaccination
Vaccines
vaccines
incidence
Incidence
Costs and Cost Analysis
childhood
Diarrhea
diarrhea
immunization
Hospitalization
Outpatients
Immunization Schedule
Immunization Programs
economic valuation

Keywords

  • Caliciviruses
  • Cost-effectiveness
  • Diarrhea
  • Gastroenteritis
  • LMIC
  • Norovirus
  • Peru
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Cost-effectiveness of norovirus vaccination in children in Peru. / Mirelman, Andrew J.; Ballard, Sarah Blythe; Saito, Mayuko; Kosek, Margaret; Gilman, Robert H.

In: Vaccine, Vol. 33, No. 27, 17.06.2015, p. 3084-3091.

Research output: Contribution to journalArticle

Mirelman, Andrew J. ; Ballard, Sarah Blythe ; Saito, Mayuko ; Kosek, Margaret ; Gilman, Robert H. / Cost-effectiveness of norovirus vaccination in children in Peru. In: Vaccine. 2015 ; Vol. 33, No. 27. pp. 3084-3091.
@article{d4b7758ece1c44ef8b5a22d9bee2717c,
title = "Cost-effectiveness of norovirus vaccination in children in Peru",
abstract = "Background: With candidate norovirus (NV) vaccines in a rapid phase of development, assessment of the potential economic value of vaccine implementation will be necessary to aid health officials in vaccine implementation decisions. To date, no evaluations have been performed to evaluate the benefit of adopting NV vaccines for use in the childhood immunization programs of low- and middle-income countries. Methods: We used a Markov decision model to evaluate the cost-effectiveness of adding a two-dose NV vaccine to Peru's routine childhood immunization schedule using two recent estimates of NV incidence, one for a peri-urban region and one for a jungle region of the country. Results: Using the peri-urban NV incidence estimate, the annual cost of vaccination would be $13.0 million, offset by $2.6 million in treatment savings. Overall, this would result in 473 total DALYs averted; 526,245 diarrhea cases averted;153,735 outpatient visits averted; and 414 hospitalizations averted between birth and the fifth year of life. The incremental cost-effectiveness ratio would be $21,415 per DALY averted; $19.86 per diarrhea case; $68.23 per outpatient visit; and $26,298 per hospitalization. Using the higher jungle NV incidence rates provided a lower cost per DALY of $10,135. The incremental cost per DALY with per-urban NV incidence is greater than three times the 2012 GDP per capita of Peru but the estimate drops below this threshold using the incidence from the jungle setting. In addition to the impact of incidence, sensitivity analysis showed that vaccine price and efficacy play a strong role in determining the level of cost-effectiveness. Conclusions: The introduction of a NV vaccine would prevent many healthcare outcomes in the Peru and potentially be cost-effective in scenarios with high NV incidence. The vaccine cost-effectiveness model could also be applied to the evaluation of NV vaccine cost-effectiveness in other countries. In resource-poor settings, where NV incidence rates are expected to be higher.",
keywords = "Caliciviruses, Cost-effectiveness, Diarrhea, Gastroenteritis, LMIC, Norovirus, Peru, Vaccine",
author = "Mirelman, {Andrew J.} and Ballard, {Sarah Blythe} and Mayuko Saito and Margaret Kosek and Gilman, {Robert H}",
year = "2015",
month = "6",
day = "17",
doi = "10.1016/j.vaccine.2015.05.004",
language = "English (US)",
volume = "33",
pages = "3084--3091",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "27",

}

TY - JOUR

T1 - Cost-effectiveness of norovirus vaccination in children in Peru

AU - Mirelman, Andrew J.

AU - Ballard, Sarah Blythe

AU - Saito, Mayuko

AU - Kosek, Margaret

AU - Gilman, Robert H

PY - 2015/6/17

Y1 - 2015/6/17

N2 - Background: With candidate norovirus (NV) vaccines in a rapid phase of development, assessment of the potential economic value of vaccine implementation will be necessary to aid health officials in vaccine implementation decisions. To date, no evaluations have been performed to evaluate the benefit of adopting NV vaccines for use in the childhood immunization programs of low- and middle-income countries. Methods: We used a Markov decision model to evaluate the cost-effectiveness of adding a two-dose NV vaccine to Peru's routine childhood immunization schedule using two recent estimates of NV incidence, one for a peri-urban region and one for a jungle region of the country. Results: Using the peri-urban NV incidence estimate, the annual cost of vaccination would be $13.0 million, offset by $2.6 million in treatment savings. Overall, this would result in 473 total DALYs averted; 526,245 diarrhea cases averted;153,735 outpatient visits averted; and 414 hospitalizations averted between birth and the fifth year of life. The incremental cost-effectiveness ratio would be $21,415 per DALY averted; $19.86 per diarrhea case; $68.23 per outpatient visit; and $26,298 per hospitalization. Using the higher jungle NV incidence rates provided a lower cost per DALY of $10,135. The incremental cost per DALY with per-urban NV incidence is greater than three times the 2012 GDP per capita of Peru but the estimate drops below this threshold using the incidence from the jungle setting. In addition to the impact of incidence, sensitivity analysis showed that vaccine price and efficacy play a strong role in determining the level of cost-effectiveness. Conclusions: The introduction of a NV vaccine would prevent many healthcare outcomes in the Peru and potentially be cost-effective in scenarios with high NV incidence. The vaccine cost-effectiveness model could also be applied to the evaluation of NV vaccine cost-effectiveness in other countries. In resource-poor settings, where NV incidence rates are expected to be higher.

AB - Background: With candidate norovirus (NV) vaccines in a rapid phase of development, assessment of the potential economic value of vaccine implementation will be necessary to aid health officials in vaccine implementation decisions. To date, no evaluations have been performed to evaluate the benefit of adopting NV vaccines for use in the childhood immunization programs of low- and middle-income countries. Methods: We used a Markov decision model to evaluate the cost-effectiveness of adding a two-dose NV vaccine to Peru's routine childhood immunization schedule using two recent estimates of NV incidence, one for a peri-urban region and one for a jungle region of the country. Results: Using the peri-urban NV incidence estimate, the annual cost of vaccination would be $13.0 million, offset by $2.6 million in treatment savings. Overall, this would result in 473 total DALYs averted; 526,245 diarrhea cases averted;153,735 outpatient visits averted; and 414 hospitalizations averted between birth and the fifth year of life. The incremental cost-effectiveness ratio would be $21,415 per DALY averted; $19.86 per diarrhea case; $68.23 per outpatient visit; and $26,298 per hospitalization. Using the higher jungle NV incidence rates provided a lower cost per DALY of $10,135. The incremental cost per DALY with per-urban NV incidence is greater than three times the 2012 GDP per capita of Peru but the estimate drops below this threshold using the incidence from the jungle setting. In addition to the impact of incidence, sensitivity analysis showed that vaccine price and efficacy play a strong role in determining the level of cost-effectiveness. Conclusions: The introduction of a NV vaccine would prevent many healthcare outcomes in the Peru and potentially be cost-effective in scenarios with high NV incidence. The vaccine cost-effectiveness model could also be applied to the evaluation of NV vaccine cost-effectiveness in other countries. In resource-poor settings, where NV incidence rates are expected to be higher.

KW - Caliciviruses

KW - Cost-effectiveness

KW - Diarrhea

KW - Gastroenteritis

KW - LMIC

KW - Norovirus

KW - Peru

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84937637600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937637600&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2015.05.004

DO - 10.1016/j.vaccine.2015.05.004

M3 - Article

C2 - 25980428

AN - SCOPUS:84937637600

VL - 33

SP - 3084

EP - 3091

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 27

ER -